CG
ATNM icon

Cutler Group’s Actinium Pharmaceuticals ATNM Stock Holding History

Cutler Group’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-8,000
Closed -$12K – 3547
2023
Q1 		$12K Buy
+8,000
New +$84.4K ﹤0.01% 2191
2022
Q2 		– Sell
-3,600
Closed -$3K – 4943
2022
Q1 		$3K Buy
+3,600
New +$19K ﹤0.01% 4406

Other funds holding ATNM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SL
Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Cutler Group's ATNM Position: Q2 2023 in Review

Cutler Group sold out of Actinium Pharmaceuticals (ATNM) in Q2 2023, closing a stake of 4,058 shares — an estimated $38K sold.

Cutler Group first reported a position in ATNM in Q3 2016 and held it in 6 quarters. The position peaked at $38K in Q1 2023. 71 funds tracked by Wall St. Rank hold ATNM as of Q2 2023.

  • Cutler Group reported no remaining Actinium Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Cutler Group sold 4,058 Actinium Pharmaceuticals shares in Q2 2023, an estimated $38K.
  • Cutler Group first reported a position in Actinium Pharmaceuticals in Q3 2016 and held it in 6 quarters.
  • Cutler Group's Actinium Pharmaceuticals position peaked at $38K in Q1 2023.
  • 71 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q2 2023.

Based on Cutler Group's 13F filing for Q2 2023, filed 18 Jul 2023.